People with a condition called wet age-related macular degeneration (AMD) often receive eye injections. These eye injections can help to improve vision and also stop the damage that causes vision to ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular degeneration, ...

In a preliminary study of 106 people with “wet” age-related macular degeneration, Johns Hopkins Medicine researchers report that as many as a third of those with the blinding retinal disease may ...

SriniVas R. Sadda, MD, looks to the future at the dawn of home diagnostics and home monitoring for patients with exudative age-related macular degeneration (wet AMD) through the promise and ...

BOSTON — A new antivascular endothelial growth-factor (VEGF) drug, OPT-302 (Opthea), appears to be safe and shows signs of effectiveness in the treatment of neovascular age-related macular ...

As many as 15 million people in the United States have some form of age-related macular degeneration, a leading cause of vision loss among people 50 and older. Nine out of 10 of them have the dry form ...

Gene therapy has the promise of being one and done, but it isn’t always that way for all patients, which leaves questions about where these therapies fit in the commercial landscape, said Charles C.

GLP-1 drugs are associated with a higher risk of “wet” age-related macular degeneration in people with type 2 diabetes, according to a new study. Researchers found that the risk substantially ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...